Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating oxaliplatin- and irinotecan-based doublet chemotherapy versus clinician's choice doublet chemotherapy for metastatic colorectal cancer
ACTRN12618001480279Phase 2Recruiting
- Sponsor
- WEHI
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, irinotecan, fluorouracil and capecitabine in colorectal cancer (CRC) (2 arms), sponsored by WEHI. Primary endpoint: Recruitment rate feasibility. Started Sep 2018; status: recruiting.
02
Drugs
oxaliplatinirinotecanfluorouracilcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12618001480279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001480279.